News & Updates
Filter by Specialty:
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
02 Dec 2021
byRoshini Claire Anthony
Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.
Milvexian prevents VTE after knee arthroplasty, bleeding risk low
02 Dec 2021Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients
02 Dec 2021
byAudrey Abella
In a pooled post hoc analysis of three phase III trials, a novel two-dose hepatitis B (hep-B) vaccine regimen trumped the traditional three-dose regimen in inducing seroprotection in patients with chronic liver disease (CLD).
Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients
02 Dec 2021Is docetaxel helpful in metastatic hormone-sensitive prostate cancer?
02 Dec 2021
Treatment with docetaxel appears beneficial in patients with low- and high-burden metastatic hormone-sensitive prostate cancer, a study has shown. However, no consistent differences for overall survival are seen in subgroup analyses as regards volume of metastatic disease.